Gallium citrate
As of the edition of 20 October 2026, Gallium citrate is a small molecule: marketed, first approved in 1982 (US); acts on RRM1, RRM2 and RRM2B; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Neoscan
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- GE Healthcare; 3 holders in all
- Registered trials
- 3, 2 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Digestive system; Immune system; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lantheus Medical Imaging | Acquired holder | 2008 to now |
| Curium | Acquired holder | 2019 to now |
| Byk-Mallinckrodt CIL | Later holder | |
| GE Healthcare | Later holder |